Navigation Links
Bionovo Announces 2009 Highlights and Year-End Financial Results
Date:3/15/2010

roups and placebo and no cases of endometrial hyperplasia or uterine cancer, further demonstrating Menerba's excellent safety profile.
  • After 12 weeks of treatment, participants taking Menerba experienced lower body mass index and weight compared to those on placebo.
  • Publication describing novel female-specific drug candidates that include Bionovo's novel plant-derived, tissue-selective estrogen receptor alpha (ER alpha) modulators (TSERaM) for the treatment of obesity.  These TSERaMs represent an exciting new class of drugs that have the potential to protect postmenopausal women from weight gain and metabolic syndrome without increasing the risks of breast and endometrial cancer like estrogens used in hormone therapy.
  • Publication of data on potential increase in breast cancer risk due to the inhibitory effect of tamoxifen treatment on estrogen receptor beta. This is an essential step in developing new strategies to prevent and treat breast cancer. The knowledge we obtained from the positive clinical effects of tamoxifen combined with recent discoveries of the different roles played by the two estrogen receptors is critical for the future generation of therapies for this important indication. Tamoxifen has been successfully used to treat and prevent breast cancer. However, some breast tumors become resistant to its effects. So, it is critical to discover new estrogens that work through a different mechanism. Bionovo has been developing methods to discover more selective drugs for breast cancer treatment and prevention and, to date, has identified numerous ER beta-selective drugs. This study provides the biological rationale for advancing ER beta drugs for the treatment of breast cancer, which potentially will be important, novel therapies for this indication.
  • Publication describing the first novel dual mTOR inhibitor (mTORC1 and mTORC2), our drug candidate BN107, for the treatment of breast cancer.  The mTOR pathway
    '/>"/>

    • SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Bionovo, Inc. to Announce Fourth Quarter and Fiscal Year 2009 Financial Results on Monday, March 15, 2010
    2. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
    3. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
    4. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
    5. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
    6. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
    7. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
    8. Bionovo Announces First Quarter 2009 Highlights and Financial Results
    9. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
    10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
    11. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/23/2013)... , May 23, 2013 Hearing health affects a ... younger, and remain socially and professionally engaged, he should address ... overriding message that the Better Hearing Institute (BHI) ... National Men,s Health Week , which leads up to ... runs from June 10 through June 16. ...
    (Date:5/23/2013)... , May 23, 2013  A recently published ... Houston, Texas , demonstrates that 3D ... increasing cancer detection. The study, "Implementation ... Observational Study," was led by Stephen L. ... issue of the American Journal of Roentgenology ...
    (Date:5/23/2013)... May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, ... companies, based on intellectual property developed and owned ... ,s foremost medical research center, today announced that ... significant funding from the Israeli Ministry of Industry ... to support product development and advance clinical trials. ...
    Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
    ... , CAMBRIDGE, Mass., Nov. 19 Ligon Discovery, ... find drugs against high-value targets, today announced that it ... Ventures. The company will use the capital to complete ... high-value disease protein targets. With this investment, incTANK Ventures ...
    ... , Part of ... Md., Nov. 19 The U.S. Food and Drug ... the International Internet Week of Action (IIWA), intended to ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , During the effort, the FDA,s Office ...
    Cached Medicine Technology:Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2
    (Date:5/23/2013)... Utah (PRWEB) May 23, 2013 Today, ... employer mandate . Zane Benefits, which provides comprehensive ... is the leader in defined contribution plans ... care reform, a common question from employees is “does ... Zane Benefits’ website, not necessarily. The health care reform ...
    (Date:5/23/2013)... (PRWEB) May 23, 2013 Onlinefitnessreview.com recently ... Blast Diet to determine what makes this diet work ... published review highlights three main components of the program: ... a positive mindset and the personal motivation that is ... every 7 days to keep the metabolism rate in ...
    (Date:5/23/2013)... City, UT (PRWEB) May 23, 2013 ... , a comprehensive radiology learning environment for all ... prebuilt lessons and assessments, transforms the learning experience ... radiology curriculum. , “Until RADPrimer 3.0, ... second to none,” comments Dr. B.J. Manaster, Professor ...
    (Date:5/23/2013)... modified version of the polio virus might one ... Scientists at Duke Cancer Institute said the ... engineered form of the virus that is harmless ... therapy shows promise in the treatment of glioblastoma, ... said. "These early results are intriguing," principal ...
    (Date:5/23/2013)... Plano, TX (PRWEB) May 23, 2013 ... the Marketplace , Chaplains have been a part of ... this Memorial Day, like those preceding it, these men ... service to the United States of America. As ... trend of their migration to the workplace chaplaincy world. ...
    Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on the Employer Mandate 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 3Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3
    ... implants created using stem cells can only be constructed ... before the almost inevitable need for total joint replacement. ... investigating the possibilities of a biologically-engineered synthetic liquid polymer ... offering a one stop, permanent solution. ...
    ... caregivers to hospital patients, coordinating and providing direct care and delivering ... ensure that each of its patient-care units has an adequate number ... number of hours nurses work known as the "target level" ... flow of patients and their need for care. Too many nurses ...
    ... By Amanda Gardner HealthDay Reporter , WEDNESDAY, March ... target levels in a large hospital, more patients died, a ... an era of nursing shortages and cost-cutting, in that the ... authors of the research, appearing in the March 17 issue ...
    ... By Amanda Gardner HealthDay Reporter , ... the tsunami that devastated the nuclear complex in Japan ... that any radiation from the unfolding disaster across the ... say. The chances of any radioactive plume reaching ...
    ... Gardner HealthDay Reporter , WEDNESDAY, March 16 (HealthDay ... treatment to show a benefit for women with a rare ... even a treatment. The drug, sirolimus (Rapamycin), improved both ... lymphangioleiomyomatosis, or LAM, according to a study published online March ...
    ... recent study from North Carolina State University shows that while ... has grown, fund support for park operations has been significantly ... growth endangers the more than $20 billion in economic impact ... the reduction in general-fund support for operations puts stress on ...
    Cached Medicine News:Health News:Liquid biomaterials take stem cell therapy to new level 2Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 2Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 3Health News:When Nurse Staffing Drops, Mortality Rates Rise: Study 2Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 2Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 3Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 4Health News:Transplant Drug May Fight Rare Lung Disorder 2Health News:Transplant Drug May Fight Rare Lung Disorder 3Health News:Study shows attendance at state parks grows, even as funding decreases 2
    ... for the quantitative determination of ... kinetic, lag phase of less ... linear phase of at least ... Linearity: 100 mg/dL (35.6 mmol/L ...
    For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
    ... the first microplate spectrophotometer designed specifically to ... per week. With rugged hardware, proven optical ... the barrier of traditional spectrophotometry to obtain ... can easily read up to eight, 1 ...
    The PerkinElmer LS 45 Luminescence spectrometer offers versatility, reliability and ease-of-use for routine analyses in an affordable package....
    Medicine Products: